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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an extremely challenging disease with a high mortality rate and a
short overall survival time. The poor prognosis can be explained by aggressive tumor growth, late diagnosis, and
therapy resistance. Consistent efforts have been made focusing on early tumor detection and novel drug development.
Various strategies aim at increasing target specificity or local enrichment of chemotherapeutics as well as imaging agents
in tumor tissue. Aptamers have the potential to provide early detection and permit anti-cancer therapy with significantly
reduced side effects. These molecules are in-vitro selected single-stranded oligonucleotides that form stable three-
dimensional structures. They are capable of binding to a variety of molecular targets with high affinity and specificity.
Several properties such as high binding affinity, the in vitro chemical process of selection, a variety of chemical
modifications of molecular platforms for diverse function, non-immunoreactivity, modification of bioavailability, and
manipulation of pharmacokinetics make aptamers attractive targets compared to conventional cell-specific ligands. To
explore the potential of aptamers for early diagnosis and targeted therapy of PDAC - as single agents and in combination
with radiotherapy - we summarize the generation process of aptamers and their application as biosensors, biomarker
detection tools, targeted imaging tracers, and drug-delivery carriers. We are furthermore discussing the current
implementation aptamers in clinical trials, their limitations and possible future utilization.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most fatal cancers burdened with a five-year overall survival
below 9% [1]. In 2018, 2.5% of the newly diagnosed cancer
cases and 4.5% of all cancer-related deaths worldwide were
attributed to PDAC [2]. A diagnosis at late disease stages,
the lack of biomarkers for screening, early metastatic dis-
semination, and ultimately the resistance to systemic therap-
ies account for the dismal prognosis of PDAC [3]. Only 20%
of patients harbor resectable cancer at the time of diagnosis
[4]. For 80% of patients with metastatic PDAC, the current
treatment options are modified (m) FOLFIRINOX (folic
acid, 5-fluorouracil, irinotecan, and oxaliplatin) or a com-
bination of nab-paclitaxel and gemcitabine in patients with
good performance status and gemcitabine with or without
a second agent for those with a poor performance status
[5]. Even for the fittest patients, who tolerate the most ef-
fective evidence-based treatment regimen FOLFIRINOX,
the median overall survival time is only 11months [6]. Fur-
thermore, targeted therapies in advanced pancreatic cancer
do not show significant improvement in survival [7]. There-
fore, it is crucial to uncover novel and reliable biomarkers/
probes for early diagnosis and surveillance. In addition,
there is an urgent need to develop targeted imaging agents
and drug delivery systems to improve PDAC prognosis.
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Aptamers have the potential to overcome difficulties of
clinical diagnosis and treatment in PDAC. These molecules
are small oligonucleotide sequences that serve as ligands to
target molecules such as proteins, bacteria, viruses, or cells.
Due to their advantages of higher tissue penetration, rapid
production, low synthesis cost, less immunogenicity, ther-
mal stability, and ease of labeling [8], aptamers are gaining
popularity as target vehicles in cancer-theranostics. Modi-
fied aptamers tagged with labeling agents function as sensi-
tive biosensors or targeted imaging tracers. As the selection
and generation can be accomplished without structural
knowledge of the target molecule, aptamers can also serve
as a tool to discover novel biomarkers [9]. Although they
were initially conceived and designed as inhibitors, a rising
number of studies reports functionally targeted agent deliv-
ery systems employing aptamers [10]. Thus, aptamers
emerge as promising tools for both diagnostic and thera-
peutic purposes.
Since 1990, Systematic Evolution of Ligands by EXponen-
tial enrichment (SELEX) became the method of choice for
generating aptamers [11]. In order to optimize that process
and synthesize aptamers more reliably and efficiently, sev-
eral improvements regarding binding conditions, library de-
sign, type of target, selection platform, and immobilization
matrix were introduced [12]. Nowadays, with the rapid
development of computer technology, the aptamer-target
interactions can be predicted without affinity experiments.
This allows more time- and cost-efficient selection and
characterization of candidate oligonucleotides [13]. In
addition to the SELEX technology, dimerization/conjuga-
tion of some aptamers increases the binding affinity and
fine-tunes the target specificity, which maximizes the possi-
bilities of various aptamer applications in the future [14].
Aptamers as aptasensors in PDAC
Aptamers have been used as ligands for the detection
step of noninvasive diagnostic assessments, such as
ELISA and other immunoassays, which are usually ap-
plied for analyzing biomarkers in blood samples. These
new aptamer-based assays, termed “aptasensors” can be
designed to integrate readout methods, such as chemilu-
minescence (CL), electro-chemoluminescence (ECL),
fluorescence, surface plasmon resonance (SPR), surface-
enhanced Raman spectroscopy (SERS), etc. [15–17], to
improve detection of existing biomarkers. Compared to
traditional techniques, the unique features of aptamers,
including ease of synthesis, quick turn-over time, low
cost, high sensitivity, and stability under different condi-
tions, render aptasensors a very promising alternative so
that they may soon replace antibody-based assays.
Carbohydrate antigen 19–9 (CA 19–9), the only routinely
used serum marker of PDAC, can specifically be bound by
an aptamer, which has been identified using a trypsin-
enhanced SELEX method. Although the dissociation
constant (Kd) value of 20.05 ± 3.02 nM showes that this
aptasensor has a high affinity to CA 19–9, it has not been
prospectively validated as aptasensor in biological fluids
[18]. Carcinoembryonic antigen (CEA), another clinically
established biomarker that improves the accuracy of PDAC
diagnostics significantly [19], can be traced by different
kinds of aptasensors [20]. Xiang and colleagues reported
aptamer-based biosensors for CEA detection [21]. The per-
formance of this aptasensor was greatly optimized and im-
proved through the combination with nanocarriers, such as
graphene, metal nanoparticles, quantum dots, etc. [20, 22].
Aptamer-based biosensors were tested for CEA measure-
ment and showed a good selectivity, excellent stability, bio-
compatibility and affinity [23]. Interleukin-6 (IL-6), a major
mediator of inflammation, is reported to be a diagnostic
biomarker or a prognostic indicator of survival in patients
with pancreatic cancer [24]. Zhuang and coworkers pre-
sented an IL-6 aptamer-based nanosensor for rapid (< 10
min), highly sensitive and specific detection of IL-6 with en-
hanced stability [25]. Mihaela and colleagues reported an
IL-6-targeted electrochemical aptasensor based on pyrrole
and gold nanoparticles, which showed high specificity and
sensitivity [26]. Metalloproteinase 9 (MMP-9), another po-
tential biomarker for diagnosis and prognostic evaluation of
pancreatic cancer [27], is involved in several important pro-
cesses of carcinogenesis, including invasion, metastasis and
angiogenesis [28]. Scarano and coworkers developed a
piezoelectric biosensor with implementation of two differ-
ent aptamers in a sandwich-like approach for real-time
measurement of MMP-9 [29].
Most of the other potential protein-based biomarkers for
early PDAC detection, including cell migration-inducing
hyaluronan binding protein (CEMIP), C4b-binding protein
α-chain (C4BPA), insulin-like growth factor-binding pro-
tein 2 (IGFBP2), insulin-like growth factor-binding protein
3 (IGFBP3), interleukin-1β (IL-1β), interleukin-8 (IL-8),
interleukin-10 (IL-10), vascular endothelial growth factor
(VEGF), and macrophage inhibitory cytokine-1 (MIC-1)
[30], could theoretically be targeted by aptamers, too. Due
to a lack of large prospective clinical trials, aptamer-based
biosensors directed against potential tumor biomarkers are
currently only established for VEGF, a key player of angio-
genesis and metastasis formation in various cancer entities
[31]. VEGF aptasensors show equivalent sensing properties
to VEGF antibodies and represent promising future tools of
clinical diagnostics [32]. Serum tested aptasensors for the
detection of established and potential PDAC biomarkers
are listed in Table 1.
Aptamers for the detection of circulating cancer cells
(CTCs) and novel PDAC biomarkers
The identification of promising predictive PDAC bio-
markers remains challenging. Circulating tumor cells
(CTCs) are single or clustered cells that loose
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connection to the tumor bulk and can be detected in the
bloodstream. They are important biomarkers for the
diagnosis and prognosis of early and metastatic cancer
[36]. Thus, sensitive techniques for CTC detection
would be crucial for early diagnosis, prognosis predic-
tion, and for monitoring treatment response via nonin-
vasive liquid biopsies. Utilizing blind cell SELEX
methods, aptamers targeting cancer cell surface struc-
tures can be enriched efficiently even without knowledge
of the protein expression profile of CTCs. After several
rounds of positive and negative selection, aptamers are
amplified, sequenced and subjected to protein mass
spectrometry to identify the detailed target structure [9].
On one hand this strategy promotes the generation of
specific aptamers for detection and therapeutic targeting
of cancer cells, on the other hand it facilitates the dis-
covery of novel CTC-based biomarkers.
To date, several aptamer-based biosensors have been
designed to identify and quantify various CTCs with de-
tection limits as low as one single cell [37]. In PDAC,
Dua and colleagues established an RNA aptamer (SQ-2)
that recognizes pancreatic cancer cells with very high
specificity. In the SELEX process they used Panc-1 and
Capan-1 cells for positive selection and normal human
pancreatic ductal epithelial (HPDE) cells for negative
selection. After sequencing the winning aptamer, they
identified alkaline phosphatase placental-like 2 (ALPP
L-2), an oncofetal protein, as the target of SQ-2 [38].
Mechanistic exploration of ALPPL-2 revealed its in-
volvement in pancreatic cancer cell growth and inva-
sion. Based on the expression of ALPPL-2 on the cell
surface and as a soluble factor in the circulation, the
authors also developed a sandwich-aptamer-linked
immobilized sorbent assay (ALISAs) targeting ALPPL-
2-positive extracellular vehicles (EVs) with high sensi-
tivity and specificity. In conclusion, SQ-2 is a possible
targeted probe for serum- and cell-based diagnostics,
and ALPPL-2 appears to be a promising future bio-
marker for PDAC [39].
Wu and co-workers used SELEX to generate a DNA-
aptamer called XQ-2d and successfully identified CD71
(transferring receptor 1) as the molecular target for cell-
specific aptamer binding [40]. Other groups developed
novel PDAC-cell-targeted aptamers, such as PL8, apta-
mer 1, and aptamer 146 [41, 42]. Even though the exact
targets of those aptamers have not been identified yet,
these molecules have the potential to detect CTCs. Re-
markably, Kim and colleagues performed SELEX while
targeting stemness-enriched PDAC cancer cells. As a re-
sult, the novel aptamer 1 and aptamer 146 were gener-
ated, which might be future candidates for the detection
of cancer stem cells (CSCs) [43].
Apart from intact PDAC cells the secretomes of PDAC
cells as well as PDAC tissues, were used for the SELEX
process. White et al. described an in-vitro positive/negative
selection strategy to identify a cyclophilin B RNA-aptamer
(M9–5) that detects structural differences between the
secretome of pancreatic cancer and non-cancerous cells.
M9–5 has the ability to discriminate sera from PDAC-
patients and healthy volunteers with high specificity and
sensitivity [44, 45]. Another aptamer (BC-15), which was
selected against human PDAC tissue, but not adjacent
normal tissue showed a high affinity for CTCs isolated
from pancreatic cancer patients. Compared to the well-
established anti-cytokeratin antibody-based method,
the BC-15 aptamer-based method showed similar effi-
cacy for the identification of CTCs. Interestingly, the
BC-15 aptamer exemplifies the potential to generate a
particular patient-specific aptamer using individual
tumor tissue as target [46]. Future applications of these
personalized aptamers include precise molecular target-
ing or surveillance of therapeutic response.










CA 19–9 None Fluorescence DNA Kd value
20.05 ± 3.02 nmol/L




ECL and SPR DNA 1.0–250 ng/mL 0.3 ng/ml Human serum [90]
CEA Ru@SiO2 − AuNPs ECL DNA 5.0–50,000 fg/mL 1.52 fg/ml Human serum [91]
CEA CdS-GR-AuNPs ECL DNA 0.01–10.0 ng/ml 3.8 pg/ml Human serum [92]
IL-6 Carbon nanotube ECL RNA 1 pg/mL to 10 ng/mL 1 pg/ml Human serum [33]
MMP-9 None SPR DNA – 0.56 ng/ml Commercial serum [29]
VEGF Quantum dots Fluorescence DNA – 50 pmol/L Human serum [34]
VEGF None ECL DNA 50 pmol/L to 0.15 nmol/L 5 pmol/L (190 pg/mL) 50% serum [35]
VEGF Carbon–gold nanocomposite ECL DNA 10 to 300 pg/ml 1 pg/ml Human serum [48]
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Aptamer-based targeted imaging of PDAC
Aptamer-based targeted imaging is one of the most
promising molecular imaging technologies for PDAC
diagnosis, accurate staging, and the monitoring of treat-
ment response. Compared to conventional imaging pro-
tocols, aptamer-based targeted imaging employs tumor-
specific, labeled aptamers to explore biological targets in
living subjects. This method harbors the following ad-
vantages: i) early detection is much easier to achieve due
to amplified imaging via aptamers targeting PDAC
markers; ii) aptamers that specifically target PDAC bio-
markers have the potential to differentiate between ma-
lignant and benign diseases; iii) more accurate imaging
helps to evaluate precise staging of PDAC and improves
surgical guidance for complete tumor resection and
lymph node clearance; iv) aptamers support the detec-
tion of biological characteristics of PDAC patients for
clinical decision making and prognostic prediction,
which can be evaluated without biopsies [47].
A few aptamer-based, PDAC-targeted imaging ap-
proaches have been evaluated in-vitro and in-vivo (Table 2,
Fig. 1). Wang and co-workers generated a DNA-aptamer
(Ap52) against the shared tumor-specific MAGE-A3111–
125 peptide antigen. Signals of the Cy3-conjugated aptamer
were specifically localized on the surface of cancer cells
from seven different entities, including pancreatic cancer.
These in-vitro results suggest that Ap52 may have poten-
tial for future molecular imaging [49]. In a xenograft
mouse model the fluorescein-labeled aptamer XQ-2d tar-
geting CD71 and the aptamer AP1153 targeting G-
protein-coupled cholecystokinin B receptor (CCKBR) ac-
cumulated particularly in PDAC tumors [40]. Therefore,
these Cy-3-labeled aptamers are promising candidates for
PDAC diagnostics.
Although there are no fluorophore-labeled aptamers
available for clinical applications, human tumor tissue
sections have been used to determine the performance
of aptamer-based imaging in PDAC patient samples.
Targeting PDAC cells with Cy-3-coupled P19/P1 aptamers
was employed as a diagnostic tool on archival human pan-
creatic duodenectomy tissue sections. Scoring patterns
from 72 patients revealed a positive correlation between
high fluorescence signal intensity and significantly increased
mortality [55]. Thus, aptamer-based, PDAC-targeted im-
aging seems to allow prognostic prediction.
Besides fluorescence imaging, magnetic resonance
imaging (MRI) is another option for PDAC-targeted
molecular imaging utilizing metal-oxide-labeled apta-
mers. Recently, a novel matrix metalloproteinase 14
(MMP14)-targeted aptamer (M17) conjugated with
polyethylene glycol-Fe3O4 was synthesized. This mol-
ecule can specifically bind to pancreatic cancer cells
in vitro and hereby reduce MRI T2-weighted imaging
signal intensity [51]. As a result, this novel molecular-
targeted MRI approach bears potential for PDAC
diagnostics.
Table 2 PDAC related diagnostic aptamers
Name Target SELEX method Positive selection Negative selection Oligos Applications Model Ref.
M9–5 Cyclophilin B Secretome MiaPaCa-2 HPDE RNA biomarker detection Patients and [45]
KPC mice serum [44]
C14B AGR2 Protein AGR2-GST GST DNA probe generation In vitro [68]
SQ-2 ALPPL-2 Cell Panc-1 HPDE RNA biomarker detection In vitro [38]
Capan-1 biosensor generation [39]
BC-15 hnRNP A1 Tissue PDAC Adjacent normal
tissue
DNA CTCs detection Patients serum [46]






PL8 HPAC Cell PL45 TOV-21G DNA New biomarker detection In vitro [41]
Apt.1 CSCs Cell HPAC (CRL2119) HPDE DNA CSCs detection; In vitro [42]
Apt.146 CSCs Cell HPAC (CRL2119) HPDE DNA New biomarker detection In vitro [42]
Ap52 MAGE-A3 Peptide MAGE-A3111–125 None DNA Cy-3-labeled fluorescence
imaging
In vitro [49]









M17 MMP14 Cell 293 T-MMP14 cells 293 T cells DNA Cy-3-labeled fluorescence
imaging
Xenograft model [51]
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Aptamer-based, molecular-targeted therapy of PDAC
In the past two decades several antibody-based,
molecular-targeted therapies were implemented for the
treatment of different hematologic and solid malignan-
cies. Unfortunately, no antibody-based targeted therapy
has yet been successful in improving the prognosis of
PDAC patients [7]. Similar to antibodies, aptamers
recognize and bind targets of interest, but they provide
numerous advantages. Aptamers are small and they can
be easily modified and linked to diverse nanoparticle sys-
tems for multi-functionalization. Other intrinsic features
include their short production time, fully chemical syn-
thesis, lower costs of manufacturing, no batch-to-batch
variability, and better thermal stability.
Several aptamers were identified for possible treatment
strategies in PDAC (Table 3). Kim and colleagues generated
a 2′-fluoropyrimidine-modified RNA-aptamer (P12FR2)
directed against pancreatic adenocarcinoma up-regulated
factor (PAUF), a novel secretory protein overexpressed in
pancreatic cancer. P12FR2 aptamers inhibited PAUF-
induced migration of PANC-1 cells in vitro and decreased
tumor growth by 60% in a PDAC xenograft mouse model
without causing relevant weight loss in treated mice [50].
Another aptamer (P15) selected by blind PDAC cell SELEX
showed significant inhibition of metastasis formation in an
in-vitro assay. P15 achieves this effect by targeting the inter-
mediate filament vimentin, an intracellular epithelial-
mesenchymal transition (EMT) tumor cell marker, which is
highly expressed as a mislocalized protein on the surface of
pancreatic cancer cells [53]. Moreover, chemically modified
aptamers against two immune checkpoint proteins, Pro-
grammed Death 1 (PD-1) and Programmed Death Ligand
1 (PD-L1) have been generated. These PD-1- and PD-L1-
aptamers could mimic antibody functions in different in-
Fig. 1 Application areas of aptamers in PDAC. Aptamers, can specifically bind target molecules and owing to their combinatorial properties for
the incorporation of therapeutics and diagnostics agents, can be used as targeted theranostic (therapeutics plus diagnostics) in PDAC. a By
specifically binding to the extracellular domain of the receptor, aptamers can work as competitive inhibitors and block cancer-related signaling in
target cells. b Instead of nucleosides, nucleoside analogs, including gemcitabine and 5-FU, can be incorporated into aptamers. These nucleoside
analog coupled aptamers can be specifically internalized and act as anti-proliferative agents. c Different kinds of oligonucleotides, including anti-
miRNAs, ASOs, miRNAs, and siRNAs, can be incorporated into aptamers. These oligonucleotides coupled aptamers can function in targeted gene
therapy in PDAC. d Aptamers can be incorporated into several multimodal drug delivery systems as carriers for targeted therapy and targeted
imaging. e By integrating different readout methods, aptamers can be used as biosensors to detect defined biomarkers, CTCs and CSCs using
aptamer-based ELISA methods. f Aptamers can be incorporated with different contrast agents to increase the sensitivity and precision of cancer
detection by targeted molecular imaging. (Abbreviations: Anti-miRNAs: microRNAs inhibitors; ASOs, antisense oligonucleotides; miRNA:
microRNAs; siRNA: short interfering RNAs; CTCs: cancer stem cells; CSCs: circulating tumor cells; ELISA: Enzyme-linked immunosorbent assay)
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vitro assays [52]. Hence, aptamers have the potential to
function as antagonists or inhibitors of crucial oncogenic
pathways due to their convincing therapeutic performance
in preclinical PDAC models.
Oligonucleotides, such as microRNAs (miRNAs),
miRNA inhibitors (anti-miRs), antisense oligonucleo-
tides (ASOs), and short interfering RNAs (siRNAs),
have been shown to potently silence the expression of
their target genes. However, one of the most signifi-
cant obstacles for oligonucleotide-based therapeutic
strategies is the lack of specific delivery to the tumor
[10]. Aptamers can recognize distinct molecules or
structures on cancer cells and get endocytosed
quickly upon binding. These intrinsic properties of
aptamers provide a chemically modifiable option of
targeted oligonucleotide delivery in the form of novel
aptamer-oligonucleotide conjugates. In order to ex-
plore the performance of aptamer-oligonucleotide
conjugates in PDAC therapy, small activating RNA
against CCAAT/enhancer-binding protein-a (C/EBPa-
saRNA) was conjugated to PDAC cell-targeted apta-
mers. These novel agents inhibited cell proliferation
in vitro and significantly reduced tumor growth in an
advanced PDAC mouse model [54, 55]. Thus,
aptamer-based targeted delivery of oligonucleotides
has potential therapeutic effects in advanced PDAC.
Nucleoside analogs are a class of drugs that are of spe-
cial interest for aptamer-based targeted treatment. Due
to the similar structure of nucleoside analogs and nat-
ural nucleosides, they can be incorporated into aptamers
rather easily. Partha Ray et al. utilized a nuclease resist-
ant RNA-aptamer that binds EGFR on pancreatic cancer
cells and is subsequently internalized in order to deliver
gemcitabine-containing polymers into EGFR-expressing
cells, which inhibited cell proliferation in vitro [56]. Dua
et al. produced an alkaline phosphatase placental-like 2
(ALPPL2) targeted RNA aptamer (SQ2) and coupled five
repeats of 5-fluoro-2′-deoxyuridine (5FdU) to the 3′-
end. Hence, one aptamer can deliver five monomer units
of the drug, while the phosphorothioate backbone en-
sures that the drug is not cleaved extracellularly by the
action of serum nucleases [65]. Yoon and co-workers de-
veloped a PDAC targeted RNA-aptamer (P19), which
was enriched with gemcitabine or 5-fluorouracil (5-FU).
They used gemcitabine triphosphate (dFdCTP) or 5-
fluorouracil (5-FU) triphosphate (5FdUTP) to replace
cytidine triphosphate (CTP) or uridine triphosphate
(UTP) during RNA-aptamer synthesis. These aptamer-
drug conjugates (ApDCs) did not only significantly in-
hibit cell proliferation in PANC-1 cells, but also inhib-
ited cell proliferation in the gemcitabine-resistant
pancreatic cancer cell line AsPC-1 [66]. Coincidentally,
Table 3 PDAC related therapeutic aptamers and aptamers-based drug delivery systems
Targeted therapy Target SELEX Preclinical model Name Chemistry Ref.
Inhibitor PAUF Protein Xenograft model P12FR2 RNA [50]
Gemcitabine EGFR Protein In vitro E07 RNA [56]
AS1411 on gold nanoparticles (AuNS)
as inhibitors
Nucleolin Designed Aptamer In vitro AS1411 DNA [61]
Doxorubicin; nanoparticles with Folic
acid/AS1411
Nucleolin Designed Aptamer In vitro AS1411 DNA [64]
Doxorubicin CD71 Protein In vitro C2-min RNA [58]
5-Fluoro-2′-Deoxyuridine ALPPL-2 Cell In vitro SQ-2 RNA [65]
Triptolide Nucleolin Designed Aptamer Xenograft model AS1411 DNA [69]
C/EBPα -saRNA HPAC Cell Xenograft model P19/P1 RNA [55]
C/EBPα -saRNA CD71 Protein Mouse model of
advanced PDAC
TR14 RNA [54]
Gemcitabine or 5-fluorouracil (5-FU) HPAC Cell In vitro P19 RNA [66]
Inhibitor Vimentin Cell In vitro P15 RNA [53]
Inhibitor PD1 Protein In vitro XA-PD1–78 DNA [52]
PD-L1 XA-PDL1–82 DNA
Monomethyl auristatin E (MMAE) CD71 Protein In vitro Waz RNA [70]
EGFR1 E07
Camptothecin Tenascin-C Protein Xenograft mice GBI-10 DNA [95]
Gemcitabine Nucleolin Designed Aptamer Xenograft mice AS1411 DNA [63]
Doxorubicin CD71 Cell In vitro XQ-2d DNA [93]
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Park and colleagues created an aptamer called APTA-12
by single substitution of a guanine residue with a gemci-
tabine phosphoramidite at position 14 of the AS1411.
APTA-12 notably inhibited the growth of pancreatic
cancer models in vitro and in vivo [63]. Thus, the gemci-
tabine- or 5-FU-incorporated aptamers represent attract-
ive tools for cancer cell-specific chemotherapeutic drug
delivery in PDAC.
The original AS1411 aptamer mentioned above is a
26-nucleotide guanosine-rich DNA-aptamer with high
affinity and specificity to nucleolin, a cell-surface recep-
tor overexpressed in cancer cells. Because AS1411 has
not only proven anti-cancer effects in models of various
cancer entities, but is also an enhancer of cellular up-
take, it is frequently used for the generation of aptamer-
based drug delivery systems [57]. According to expecta-
tions, it was reported that an increased loading density
of AS1411 on gold nanostars (AuNS) rises the quantity
of AS1411 delivered into pancreatic cancer cells, which
finally results in substantial pancreatic cancer cell death
[61]. Lale et al. developed a dual-targeted, pH-sensitive,
biocompatible polymeric nano-system conjugated with
doxorubicin. This dual approach with folate and the
AS1411 aptamer successfully increased the cancer-targeting
efficiency of the nanoparticles resulting in a higher payload
of doxorubicin in PDAC cell lines [64]. Also, the herb-
derived compound triptolide (TP) can also increase anti-
tumor activity in vitro and in vivo when coupled to an
AS1411-linked polymeric nanocarrier [69]. These studies
open new perspectives for overcoming drug resistance of
pancreatic cancer.
CD71 (transferrin receptor) and EGFR are also com-
monly used targets in aptamer-guided therapy of PDAC.
Several groups loaded doxorubicin, monomethyl aurista-
tin E (MMAE), or monomethyl auristatin F (MMAF) to
CD71- or EGFR-targeted aptamers, respectively [58, 70].
Their ability to dampen the proliferation of pancreatic
cancer cells makes these aptamers attractive options for
delivery of toxic substances specifically into PDAC cells.
Aptamers in clinical trials
Since pegaptanib, an RNA-aptamer directed against
VEGF165, was approved by the US Food and Drug Admin-
istration (FDA) as an anti-angiogenic treatment for neo-
vascular (wet), age-related, macular degeneration (AMD)
in 2004, an increasing number of aptamers have success-
fully entered clinical trials. Until now, three aptamers have
entered phase III. The protagonists are Pegnivacogin
(RB006), a direct factor IXa inhibitor; E10030, an anti-
platelet-derived growth factor (anti-PDGF-B) aptamer;
and Zimura, a complement factor C5-inhibitor [59].
So far, NOX-A12 is the only aptamer undergoing a
clinical trial for pancreatic cancer [8]. NOX-A12 is an
RNA-aptamer that targets CXCL12 (C-X-C Chemokine
Ligand 12), a key chemokine protein involved in tumor
cell proliferation, the formation of new blood vessels and
metastasis. As a novel CXCL12 inhibitor, NOX-A12 was
found to be safe and well-tolerated by 28 patients with
relapsed or refractory multiple myeloma in a phase 2a
study (NCT01521533) [62]. Twenty patients with meta-
static microsatellite-stable (MSS) colorectal or pancreatic
cancer were recruited in the Opera study (NCT03168139)
to evaluate the efficacy of NOX-A12 plus pembrolizumab
(PD-1 antibody) treatment. The results demonstrated that
25% of patients achieved stable disease and 35% of pa-
tients showed a prolonged survial time on treatment in
comparison to the prior line of therapy. The safety profile
of the combination therapy was consistent with that of
pembrolizumab alone in advanced cancer patients. There-
fore, NOX-A12 displayed both safety and therapeutic po-
tential in combination with pembrolizumab. More clinical
trials are needed to explore the efficacy of several more
aptamers in PDAC treatment [67].
Aptamers in combination with radiation therapy
In order to improve the therapeutic outcome of clinical
PDAC treatment, it seems inevitable to design novel
strategies that combine different treatment modalities
aiming at achieving synergism [60]. However, the im-
proved efficacy of combined systemic therapies often
comes at the costs of severe side effects. Accordingly,
local therapies move into the focus of combined modal-
ity settings. Radiotherapy is a longstanding and essential
component of multimodal cancer treatment [60]. For
many solid tumor entities, combination regimens of
chemo- and radiotherapy represent the standard of care
(e.g., locally advanced head and neck cancers or glio-
blastoma) [71]. However, for the treatment of PDAC,
radiotherapy is rather infrequently applied, because the
majority of patients present in disseminated disease
stages, and PDAC is well known for its high degree of
radioresistance [72]. Aptamers represent versatile tools
to bypass this radioresistance due to their high target
specificity, straightforward synthesis, stability in different
conditions and body fluids and the abundant spectrum
of possible modifications as described in the previous
sections.
Three strategies for the combination of aptamers and
ionizing radiation can be found in the literature. The
first strategy uses aptamers, which exhibit radiosensitiz-
ing properties per se without any further conjugation
since binding to their designated targets interferes with
radioresistance signaling (Fig. 2a). This was successfully
shown in a glioblastoma (GBM) cell model, where the
EGFRvIII-specific DNA-aptamer increased the radiosen-
sitivity of EGFRvIII-expressing U87 cells, besides inhib-
ition of proliferation, migration, and invasion [73]. The
authors speculated that increased radiosensitivity with
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U2 treatment in GBM cells might occur through de-
creasing the ATP supply and inhibiting the signaling
molecules in the common pathways induced by EGFR-
vIII and MET and thus inhibition of the DNA damage
response.
The second radiosensitizing strategy utilizes aptamers
as vehicles for radiosensitizing compounds (Fig. 2b).
This group of aptamers can be subdivided according to
the nature of their modification into aptamers which (i)
deliver metal (nano-)formulations, (ii) incorporate mole-
cules targeting the DNA damage response (DDR), and
(iii) transport chemotherapeutics.
Aptamers with metal (nano-)formulations
Aptamers of this group enforce the biological effects of
radiation by physical dose enhancement via photoelec-
trons, Auger electrons, and secondary electrons that are
generated from irradiated metal particles [74] (Fig. 2b
left panel). This, in turn, leads to an increase in the
levels of free radicals in tumor cells and enforced DNA
damage. One example of aptamers in this group is the
already mentioned AS1411 aptamer against cell surface
nucleolin. A gold nanocluster conjugate of the AS1411
aptamer enhanced the efficacy of radiation therapy in
breast tumor-bearing mice. Importantly, the authors re-
ported a specific enrichment of the radiosensitizing gold
nanoclusters in the breast tumors and a significant in-
crease in the mean survival times of the animals [75].
Analogously, the combination of silver nanoparticles
with polyethylene glycol (PEG)-functionalized AS1411
aptamer improved the outcome of radiation therapy in
preclinical glioma models. Significantly prolonged me-
dian survival times were shown in animals undergoing
the combined aptamer radiotherapy protocol vs. aptamer
treatment alone [76]. Apart from metal formulations,
the anti-MUC1 aptamer was conjugated to the radiosen-
sitizer 1,10 phenanthroline for in-vitro radiosensitization
of breast cancer cells, although the actual radiosensitiz-
ing potential of this complex has not yet been fully
proven [77]. None of those mentioned above approaches
used a preclinical PDAC model. Nevertheless, since the
AS1411 aptamer has been shown to potently bind to
Fig. 2 Different strategies of aptamer-based combined modality approach with radiotherapy. Aptamers specifically bind to the target structures
(e.g. EGFR, PSMA, MUC-1, nucleolin, etc.), endocytosed and released in the cytoplasm following lysosomal degradation (a) Aptamer-binding to
designated target interferes with radio-resistance signaling and sensitize radiotherapy. b Several radiosensitizers, such as metal formulations,
siRNAs and nucleoside analogs can be coupled with aptamers for targeted delivery into cancer cells to sensitize radiotherapy. c Therapeutic
radionuclides can be incorporated into aptamers for targeted radiotherapy. d These aptamers (re-)activate systemic anti-tumor immune responses
by targeting immune checkpoint activation related receptors, enable antitumoral immunity and possible abscopal effects
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PDAC cells in other studies, and since MUC1 is
expressed in PDAC cells as well [78], metal (nano) for-
mulations of both the AS1411- and the anti-MUC1-
aptamer could potentially be used as radiosensitizers for
pancreatic cancer.
Aptamers with molecules targeting components of the
DDR
Aptamers in this category enhance the biological effect-
iveness of radiotherapy by their conjugation to sub-
stances that interfere with the DNA damage response
(e.g., siRNAs targeting crucial DDR regulators, Fig. 2b
middle panel). This treatment strategy was successfully
reported in an approach with targeted administration of
DNA-PK silencing siRNA by aptamer-siRNA chimeras
against prostate-specific membrane antigen (PSMA) in
experimental models of prostate cancer. Upon aptamer
treatment, an increase in radiation-induced cytotoxicity
(based on specific DNA-PK knockdown) was achieved
in vitro in a PSMA-positive prostate cancer cell line.
The subsequent in-vivo evaluation with xenotransplants
showed a PSMA-specific, significant delay in tumor
growth upon the combination of aptamer treatment and
radiotherapy with 6 Gy, which was not observed without
irradiation or in non-PSMA expressing tumors, respect-
ively [79, 80]. These data further strengthen the PSMA-
and therefore tumor-specific nature of aptamer-mediated
radiosensitization and underline the attractiveness of this
approach in combination with local radiotherapy. Since
PSMA expression has also been shown in PDAC [81],
PSMA targeting aptamers in combination with radiother-
apy may represent an exciting option for PDAC treatment
and should be investigated in more detail.
An example of combining several of the mentioned
aptamer strategies in one molecule is the AuNP-NUAP-
STAT3d aptamer, which is targeted against nucleolin
and is conjugated with gold nanoparticles and a STAT3
antagonizing decoy payload, again emphasizing the easy-
to-modify nature of aptamers. The AuNP-NUAP-
STAT3d aptamer was described to potently radiosensi-
tize head and neck squamous cell carcinoma (HNSCC)
cells by combining tumor-specific radical-amplifying
gold nanoclusters and tumor-specific inhibition of
STAT3 signaling [82].
Targeted delivery of chemotherapeutics
As a third approach of aptamer-based radiosensitization,
target-specific radiochemotherapy regimens that com-
bine aptamers with chemotherapeutic agents are cur-
rently being investigated (Fig. 2b right panel). As
already described, pyrimidine analogs, such as 5-FU and
gemcitabine, can directly be integrated into the molecu-
lar structure of aptamers thereby optimizing therapeutic
drug delivery. Analogously, aptamers were also modified
for the delivery of therapeutic radionuclides (Fig. 2c).
However, the latter approach is currently explored
mainly for diagnostic, but not for therapeutic pur-
poses [83]. The only therapeutic approach that has
been reported so far is the combination of PEGylated
liposomes loaded with the α-particle emitter 225Ac
and with anti-PSMA aptamer A10 for the experimen-
tal treatment of prostate cancer models [84]. Apart
from anti-PSMA aptamer A10 labeled α-particle emit-
ter 225Ac loaded PEGylated liposomes, anti-PSMA
antibody labeled ones were also generated for evalu-
ation of their selectivity, internalization potential and
killing efficacy. The results showed that the antibody
was more efficient than the aptamer in terms of cyto-
toxicity and lethal dose values [84]. However, the
comparison between antibodies and aptamers does
not consider the distinction between affinity and avid-
ity. Moreover, this difference could be explained by
the double number of antibodies on the surface of
the liposome compared to the number of aptamers.
Each antibody has two binding sites, whereas one
aptamer only has one binding site. Based on the cal-
culation from de Almeida and colleagues for this case,
antibody labeled liposomes owned 4 times higher
binding capacity, but showed 1.5–1.7 times lower le-
thal dose values compared to aptamer labeled lipo-
somes [83]. Thus, aptamer could be equal or better
than the antibody as a delivery agent.
The third strategy is a very complex approach which
made use of aptamers that were modified to (re-)activate
anti-tumor immune responses (Fig. 2d). In a breast can-
cer mouse model, irradiation-induced upregulation of
VEGF was instrumentalized to enable tumor-specific en-
richment of a dual-modified aptamer against VEGF and
costimulatory 4-1BB T cell antigen. The aptamer showed
similar efficacy with regards to tumor control as com-
pared to conventional, stimulatory 4-1BB antibodies, but
– due to its tumor-specific delivery – relevantly less tox-
icity. Notably, systemic immune responses were (re-)ac-
tivated, resulting in the control of distant metastatic
tumor lesions outside the irradiation field. These find-
ings underline the potential of tumor stroma-targeted
aptamers to modulate anti-tumor immune mechanisms
in combination with radiation [85, 86].
Although aptamers in combination with radiation
therapy are rarely explored in pancreatic cancer, the
strategies we summarized above provide us promising
approaches to sensitize radiotherapy in several cancers.
Considering the high degree of radioresistance in PDAC,
these aptamer-based radiosensitizing treatments supply
us with novel ideas to decrease its radioresistance and
maybe improve the prognosis in the future, especially re-
garding the emerging new technical possibilities of
image-guided irradiation (e.g. MR-Linac).
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Conclusion and perspectives
As described in this review, aptamers are very useful
tools and have several applications in the diagnosis and
therapy of pancreatic cancer. Unique features including
ease of synthesis, high sensitivity and specificity and sta-
bility in different conditions, render aptasensors an in-
teresting choice for the detection of biomarkers, CTCs,
and CSCs. Additionally, aptamer-based biosensors repre-
sent ideal noninvasive devices for PDAC diagnosis even
in early tumor stages. With help of the blind SELEX
method, aptamers are able to identify novel biomarkers
from cancer cells, secretomes, membranes or tissues,
which can stimulate novel ideas for screening attempts
and new hypotheses for mechanistic studies. Aptamer-
based in-vivo imaging is an excellent way to obtain com-
prehensive images and molecular information without
invasive biopsies. Data from aptamer-enhanced technolo-
gies will support clinical decision making and enhance the
quality of precise prognostic prediction. Importantly, as
aptamers can exert several ways of action, they are attract-
ive tools for targeted therapy of PDAC, alone or in com-
bination with standard approaches, such as radiotherapy.
Aptamers can work as inhibitors and drug carriers. Their
excellent performance in targeted inhibition renders them
competitive alternatives to antibodies. Diverse aptamer-
based drug delivery systems with incorporated nucleoside
analogs, oligonucleotides, and other drugs allow aptamers
to guide targeted chemotherapy or RNA interference into
PDAC cells.
However, the application of aptamers has some limita-
tions. Significant problems include degradation in blood
and high renal excretion [87], although the molecules
can be modified to increase plasma half-life. For RNA-
aptamers, which are usually degraded by nucleases in
biological media, modifications of 3′- and 5′-ends pro-
vide resistance to exonucleases, and modifications on 2′-
position protect against endonucleases [88]. In order to
prolong aptamer circulation in the bloodstream, conju-
gation with polyethylene glycol (PEG) is a commonly
used strategy that increases the half-life of PEG-
conjugated aptamers up to several days [89].
With the development and advancement of aptamers,
these molecules are becoming an attractive platform for
translational applications. To make the best use of apta-
mers, future directions should focus on aptamer-based
biosensors and aptamer-based, targeted drug-delivery
systems – particularly systems for nucleoside analogue
and oligonucleotide delivery for combined modality
treatment approaches.
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